The present invention relates to an assay for evaluating alveolar exchange of oxygen. A 13C-labeled substrate, such as 13C-sodium bicarbonate is administered to a subject by oral or iv intake, and exhaled 13CO2 is measured. The 13CO2 in expired breath can be collected at various time points following administration of the substrate and measured in Δ per mil with a mass analyzer or photometer, such as an IR spectrometer. This process can be used as a diagnostic test for the indication of, treatment and/or evaluation of the severity of respiratory tract diseases or infections.
|
1. A method for evaluating alveolar gas exchange, comprising:
administering a 13C-labeled substrate to a subject;
measuring 13CO2 exhaled by the subject; and
determining lung function from the measured 13CO2.
14. A method of diagnosing the severity of a respiratory tract disease or infection, comprising:
administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection;
measuring 13CO2 exhaled by the subject; and
diagnosing the severity of the respiratory tract disease or infection based on the amount of 13CO2 exhaled by the subject.
19. A method of determining the presence of a respiratory tract disease or infection, comprising:
administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection;
measuring 13CO2 exhaled by the subject; and
determining lung function from the measured 13CO2;
wherein the lung function is indicative of the presence of the respiratory tract disease or infection.
24. A method of detecting a respiratory tract disease or infection or the severity of a respiratory tract disease or infection, comprising:
administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection;
measuring 13CO2 exhaled by the subject; and
detecting the respiratory tract disease or infection or the severity of a respiratory tract disease or infection based on the amount of 13CO2 exhaled by the subject.
25. A method of monitoring the severity of a respiratory tract disease or infection, comprising:
administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection;
measuring 13CO2 exhaled by the subject at first and second points in time;
determining the severity of the respiratory tract disease or infection based on the amount of 13CO2 exhaled by the subject at said first point and second in time;
determining the severity of the respiratory tract disease or infection based on the amount of 13CO2 exhaled by the subject at a second point in time.
2. The method according to
3. The method according to
4. The method according to
5. The method according to
6. The method according to
7. The method according to
8. The method according to
9. The method according to
10. The method according to
11. The method according to
12. The method according to
t0, a time prior to ingesting the 13C-labeled substrate;
t1, a time after the 3C-labeled substrate has been absorbed in the bloodstream of the subject; and
t2, a time during the first elimination phase.
13. The method according to
slope={(Δ 13CO2)2−(Δ 13CO2)1}/(t2−t1) wherein Δ 13CO2 is the amount of exhaled 13CO2.
15. The method according to
16. The method according to
18. The method according to
20. The method according to
21. The method according to
22. The method according to
23. The method according to
|
|||||||||||||||||||||||||||||||||
This application claims the benefit of priority from U.S. Provisional Application No. 60/359,862, filed Feb. 27, 2002, the disclosure of which is incorporated herein in its entirety.
The present invention relates, generally, to a method of evaluating lung function via a breath assay, by determining the relative amount of 13CO2 exhaled upon iv or oral administration of a 13C-labeled substrate, such as sodium bicarbonate. This process can be used as a diagnostic assay for the treatment and evaluation of respiratory tract diseases or infections and their severity.
Over 40 million individuals in the U.S. suffer from any one of the following respiratory tract diseases or infections: chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, or other respiratory afflictions. Worldwide, the most serious diseases continue to grow at alarming rates. The prevalence of asthma increased 75% between 1980 and 1995, and an estimated 10% of the population over 64 suffers from COPD. According to statistics from the World Health Organization, COPD is projected to be the 5th leading cause of disease by the year 2020. Americans spend over $6.0 billion/year for treatment of respiratory distress.
There are five main categories of treatment available for COPD:
1. Bronchodilators, such as albuterol, pirbuterol, isoetherine, metaproteranol, terbutaline, salmeterol.
2. Anti-Inflammatories (Steroids), such as prednisone, methylprednisolone.
3. Oxygen
4. Lung Reduction Surgery
5. Transplant Surgery
A number of pulmonary function tests (PFT's) are routinely carried out to evaluate the overall performance of lungs. These take from 1-3 hours depending on the tests. These tests include, for example, spirometry, sputum test, lung volume tests, diffusing capacity test, methacholine challenge tests (testing for asthma), allergen bronchial challenge tests (testing for specific allergies), airway resistance test (looking for obstruction in the large airways), and lung compliance test (measuring the elasticity of the lungs, which is reduced in emphysema). X-ray analysis is the diagnostic tool of choice for occupational diseases caused by work environment pollutants, such as, silica, coal, cement, asbestos, smoke, coal dust, etc.
Most of these tests, however, are useful only for evaluating lung capacity, and not lung function. Lung capacity and airway resistance measured by spirometry generally relates to a volume of gas expired by a particular set of lungs. Lung function, in contrast, is the capability of the lung to provide oxygen to the blood and remove carbon dioxide, i.e., the ability to perform alveolar gas exchange efficiently. Any lung obstruction caused by environmental pollutants can affect the extent of alveolar gas exchange, either by slowing down the inhalation of oxygen, the exhalation of carbon dioxide, or both. Lung function, thus, provides a more reliable diagnostic tool for obstructive respiratory problems than lung capacity, as it relates to the efficiency of the gas exchange process.
The only lung function assay available of any clinical significance is Arterial blood gas (ABG). The ABG test produces four main measurements: arterial pH, paO2, paCO2 and HCO3−. The arterial pH is a measure of the body's acid-base equilibrium. Any major alteration of the pH (normal levels 7.35-7.45) can prove fatal. The arterial paO2 indicates the oxygenation of the blood (normal levels 80-100 mmHg). A low paO2 can also prove fatal and appropriate oxygen therapy is usually given to correct a low paO2. The ability to excrete CO2 is one of the major respiratory functions of the lung, and the arterial paCO2 measures the ability of the body to excrete carbon dioxide (normal levels 35-45 mmHg). An elevated paCO2 may suggest a problem with lung ventilation that could progress to require mechanical ventilation. The importance of bicarbonate (HCO3−) lies in its role as the renal or metabolic component of acid-base regulation, with normal HCO3− levels being 22-28 mEq/L. ABG is, however, an invasive and painful test.
Accordingly, there remains a continuing need to develop an assay to determine lung function.
One embodiment of the present invention provides a method of evaluating alveolar gas exchange. The method comprises administering a 13C-labeled substrate to a subject, measuring 13CO2 exhaled by the subject, and determining lung function from the measured 13CO2.
Another embodiment of the present invention provides a method of treating a respiratory tract disease or infection. The method comprises administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection, measuring 13CO2 exhaled by the subject, selecting a treatment for the respiratory tract disease or infection, and treating the respiratory tract disease or infection.
Another embodiment of the present invention provides a method of determining the presence of a respiratory tract disease or infection. The method comprises administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection, measuring 13CO2 exhaled by the subject, and determining lung function from the measured 13CO2, wherein the lung function is indicative of the presence of the respiratory tract disease or infection.
Another embodiment of the present invention provides a kit comprising a 13C-labeled substrate, and instructions provided with the substrate that describe how to determine lung function.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.
The accompanying drawings, which are incorporated in and constitute a part of this specification, illustrate several embodiments of the invention and together with the description, serve to explain the principles of the invention.
Recently, a number of breath tests using either radioisotope labeled 14C-sodium bicarbonate or stable isotope labeled 13C-sodium bicarbonate have been described for evaluating various biological functions such as atrophic gastritis, energy expenditure, H.pylori infection, euglycaemic hyperinsulinaemia and gastric emptying. None of these tests, however, has been applied to the diagnostic purpose of indicating the presence of, diagnosing, or stratifying the severity of respiratory tract diseases or infections.
One embodiment of the invention provides a method of evaluating the efficiency of alveolar gas exchange, i.e., gas exchange involving air cells of the lungs, as distinguished from tissue gas exchange. The method generally involves administering a 13C-labeled substrate to a subject and monitoring the alveolar gas exchange by measuring an exhaled gas, such as 13CO2. In one embodiment, the 13C-labeled substrate can be a carbonate, such as 13C-sodium bicarbonate. For example, when ingested, a bicarbonate substrate undergoes an acid/base reaction in the gastrointestinal tract and releases HCO3−. The HCO3− is converted to carbon dioxide, which is subsequently released as carbon dioxide from the body by exhalation.
The substrate can be administered non-invasively, such as by oral administration through ingesting a tablet, a powder or granules, a PTP formulation, a capsule, or a solution. Alternatively, the substrate can be administered intravenously.
In one embodiment, the subject is a mammal. In another embodiment, the subject is a human.
In one embodiment, the method comprises measuring the 13CO2 exhaled by the subject. The 13CO2 can be measured by any method known in the art, such as any method that can detect the amount of exhaled 13CO2. For example, 13CO2 can be measured spectroscopically, such as by infrared spectroscopy. One exemplary device for measuring 13CO2 is the UBiT®-IR300 infrared spectrometer, commercially available from Meretek (Denver, Colo.). The subject, having ingested the 13C-labeled substrate, can exhale into a breath collection bag, which is then attached to the UBiT®-IR300. The UBiT®-IR300 measures the ratio of 13CO2 to 12CO2 in the breath. By comparing the results of the measurement with that of a standard, the amount of exhaled 13CO2 can be subsequently calculated. Alternatively, the exhaled 13CO2 can be measured with a mass analyzer.
In one embodiment, lung function is determined from the measured exhaled 13CO2. Lung function can indicate the capability of the lung to efficiently perform cellular respiration. As a result, lung function can provide a reliable property for diagnosing or monitoring respiratory tract diseases or infections.
In one embodiment, lung function is determined by an area under the curve (AUC), which plots the amount of exhaled 13CO2 on the y-axis versus the time after the 13C-labeled substrate is ingested.
Δ 13CO2(‰)=(δ 13CO2 in sample gas)−(δ 13CO2 in baseline sample before ingestion)
where δ values are calculated (in ‰) by ={(Rsample/Rstandard)−1}×1000, and “R” is the ratio of the heavy to light isotope (13C/12C) in the sample or standard. The area under the curve represents the cumulative Δ 13CO2 (‰)×hour.
An individual who develops a respiratory tract disease or infection may show a reduced AUC value compared to a population of healthy individuals (or to another individual given a weight-related dose). Referring to
The method of the invention can be used, for example, as a diagnostic tool. In one embodiment, the AUC curves are compared with those of another individual or a population of individuals. It is generally believed that the amount of exhaled 13CO2 is dependent on the body size or weight of the subject. In one embodiment, when comparing AUC values of a patient with another individual, the patient is administered a weight-adjusted dose and compared to another individual who was also administered a weight-adjusted dose. If the patient is compared to a population, the population may be given weight-related doses. In another embodiment, the AUC values are used to monitor an individual's lung function over time. In this embodiment, a weight-related dose is not necessary. Here, the patient can be given any dose, so long as the dosage remains fixed for that individual each time the test is administered.
In another embodiment, lung function can be evaluated by determining the slope of a time and dose response curve where the breath curve exhibits first order decay. In one embodiment, the Δ 13CO2 (‰) values are measured at the following time periods:
t0, the time prior to ingesting the 13C-labeled substrate;
t1, the time after the 13C-labeled substrate has been absorbed in the bloodstream of the subject; and
t2, the time during the first elimination phase.
In this embodiment, the slope of the Δ 13CO2 curve at time points t1 and t2 is calculated according to the following equation:
slope={(Δ 13CO2)2−(Δ 13CO2)1}/(t2−t1)
As an example, the slope of the curve of
In one embodiment, where the slope method is used to determine lung function to compare the lung function of different individuals, the use of weight-adjusted doses is not necessary.
Another embodiment of the present invention provides a method of monitoring treatment, or diagnosing a respiratory tract disease or infection. The method comprises administering a 13C-labeled substrate to a subject suspected of having the respiratory tract disease or infection, such as any 13C-labeled substrate described herein. The method further comprises measuring 13CO2 exhaled by the subject. In one embodiment, the results of the measured 13CO2 can indicate or confirm the presence of at least one respiratory tract disease or infection.
In another embodiment, the invention provides a method of treating a respiratory tract disease or infection. From the results of the measured 13CO2, as discussed above, a treatment for the respiratory tract disease or infection can be selected or optimized. The method further comprises treating the respiratory tract disease or infection.
In one embodiment, the treatment is selected from administering a drug, selecting a drug dosage, and oxygen therapy, such as optimized oxygen therapy during the process of weaning a patient from oxygen. For example, depending on the respiratory tract disease or infection, a physician may choose a certain drug to treat the patient. Alternatively, if the patient is already taking a drug, the results of the test may cause a physician to increase or lower the dosage of the drug, depending on the severity of the disease or infection. Another type of treatment is oxygen therapy, where oxygen is administered to a patient to improve the oxygen balance in the blood. In yet another alternative, the results of the test may indicate if the patient should terminate or resume treatment, such as oxygen therapy.
Representative respiratory tract diseases or infections that can be diagnosed or monitored in accordance with the invention include, but are not limited to, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, silicosis, side effects of lung transplantation, bronchitis, bronchiolitis, emphysema caused by alpha 1-antitrypsin deficiency, the common cold, croup, diphtheria, epiglottitis, influenza, lung cancer, measles (rubeola), pertussis (whooping cough), pleurisy, pneumonia, pneumonicosis (such as asbestosis, silicosis, coal workers pneumoconiosis, chronic beryllium disease, and allergic alveolitus), pneumothorax, pulmonary embolism, pulmonary fibrosis, rubella (German measles), rhinitis, sarcoidosis, scarlet fever, sinusitis, sore throat, streptococcal infections, and tuberculosis, and other respiratory afflictions. Thus, this aspect of the invention can be of use to a physician for ascertaining disease status, progression, and drug treatment.
In one embodiment, the measured 13CO2 is used to determine lung function. In one embodiment, the lung function can be quantified to determine whether the subject falls above or below a threshold value. This determination can be used to monitor an individual over the course of treatment, where the threshold value is varied for each individual. In one embodiment, the individual is tested at a fixed dosage each time the test is administered. In another embodiment, the threshold value can be determined from a population of individuals tested with a weight-adjusted dose.
In one example, the method can be used for treating and monitoring asthma patients. There are a variety of medications available to relieve respiratory distress (airway passage inflammation). The selection of the proper medication, with a favorable safety profile, can aid in effectively treating asthma patients. Physicians often rely on pulmonary function tests like spirometry—improvements in traditional measures such as FEV1 and PEFR (peak expiratory flow rate)—to help monitor the level of distress in asthma patients. Medications such as corticosteroids (inhaled), Beta 2 Agonists (inhaled) and oral corticosteroids need to be used with utmost caution due to numerous side-effects. The methods described herein can be used to monitor the reduction of airway resistance to individualize medication, e.g., to select and adjust dosage of drugs.
Another embodiment of the invention provides a kit for determining lung function. The kit can include a 13C-labeled substrate, such as 13C-sodium bicarbonate, and instructions that describe how to determine lung function. The 13C-labeled substrate can be supplied as a tablet, a powder or granules, a PTP formulation, a capsule, or a solution. The instructions can describe the method for determining lung function by using the area under the curve, or by the slope technique, as described above.
The kit can optionally include at least three breath collection bags, for measuring the exhaled 13CO2 at times t0, t1, and t2. More breath collection bags may be used if additional time periods are necessary. If the 13C-labeled substrate is supplied as a solid, the kit can also include a container for dissolving the substrate.
In one embodiment, the methods to determine lung function, as described herein, can enable the differentiation of gaseous exchange (O2 and 13CO2) between healthy individuals and those with pulmonary disorders. The method can be non-invasive, only requiring that the subject perform a breath test. The present test does not require a highly trained technician to perform the test. The test can be performed at a general practitioners office, where the analytical instrument (such as, for example, a UBiT®-IR300) is installed. Alternatively, the test can be performed at a user's home where the home user can send breath collection bags to a reference lab for analysis. In contrast, the ABG test requires skilled personnel to take arterial blood samples and carry out careful and immediate determination of pO2 and pCO2.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and the examples be considered as exemplary only.
Breath test procedure. Water (100 mL) is added to 13C-sodium bicarbonate (100 mg) in a 120 mL graduated COrning Snap seal plastic vial (No. 1730-8). The solution is ingested, after overnight fasting, over a time period of approximately 10-15 seconds. Breath samples are collected at 5 minute time points up to 20 minute and then at 30, 40, 50, and 60 minutes after ingestion of 13C-sodium bicarbonate. The breath samples are collected by momentarily holding the breath for 3 seconds prior to exhaling into the sample collection bag. The breath samples are analyzed on a UBiT IR-300 spectrophotometer sold by Meretek, Denver, Colo., to determine the 13C/12C ratio in expired breath, or sent to a reference lab.
This example describes the monitoring of the reduction in airway resistance in one asthma patient following inhaler medication therapy—advair (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) and albuterol (racemic (α1-[(tert-butylamino)methyl]-4-hydroxy-m-xylene-α,α′-diol, commercially available as Ventolin®, Proventil®) a relatively selective beta2-adrenergic bronchodilator.
A breath test was performed at 7 am before the patient ingested any asthma medication. The medication was taken at 8:15 am. The breath test 45 minutes post medication (9 am) shows an improvement in both the AUC (cumulative‰×h) and possibly the slope (steepening) between 10-20 minutes compared to the pre-medication breath test as seen in FIG. 4.
| Patent | Priority | Assignee | Title |
| 11432744, | Sep 28 2016 | INDIAN INSTITUTE OF TECHNOLOGY, GUWAHATI | Lung condition monitoring device |
| 8221327, | Sep 18 2003 | Cardiac Pacemakers, Inc. | Therapy control based on cardiopulmonary status |
| 8435187, | Nov 30 2005 | Wisconsin Alumni Research Foundation | Identification of disease characteristics using isotope ratios in breath |
| 8852117, | Nov 30 2005 | Wisconsin Alumni Research Foundation | Identification of disease characteristics using isotope ratios in breath |
| 8915741, | Aug 18 2003 | Cardiac Pacemakers, Inc. | Sleep quality data collection and evaluation |
| Patent | Priority | Assignee | Title |
| 5386832, | Jun 11 1993 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC , THE | Liver function breath test using aromatic amino acids |
| 5848975, | Jul 01 1996 | St. Vincent's Medical Center of Richmond | Breath test for helicobacter pylori |
| 5962335, | Jan 03 1997 | EXALENZ BIOSCIENCE LTD | Breath test for detection of drug metabolism |
| 6312390, | Mar 26 1997 | Breath test for detection of lung cancer | |
| 6726327, | May 31 2000 | ESSILOR INTERNATIONAL, S A | Method and apparatus for testing the vision of a video display terminal user |
| EP966975, | |||
| WO41623, | |||
| WO187352, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Feb 26 2003 | Cambridge Isotope Laboratories | (assignment on the face of the patent) | / | |||
| Mar 04 2003 | IRIE, YASUO | Cambridge Isotope Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014081 | /0607 | |
| Mar 04 2003 | MODAK, ANIL S | Cambridge Isotope Laboratories | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 014081 | /0607 |
| Date | Maintenance Fee Events |
| Nov 10 2008 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Dec 24 2012 | REM: Maintenance Fee Reminder Mailed. |
| Jan 24 2013 | RMPN: Payer Number De-assigned. |
| May 10 2013 | EXP: Patent Expired for Failure to Pay Maintenance Fees. |
| Date | Maintenance Schedule |
| May 10 2008 | 4 years fee payment window open |
| Nov 10 2008 | 6 months grace period start (w surcharge) |
| May 10 2009 | patent expiry (for year 4) |
| May 10 2011 | 2 years to revive unintentionally abandoned end. (for year 4) |
| May 10 2012 | 8 years fee payment window open |
| Nov 10 2012 | 6 months grace period start (w surcharge) |
| May 10 2013 | patent expiry (for year 8) |
| May 10 2015 | 2 years to revive unintentionally abandoned end. (for year 8) |
| May 10 2016 | 12 years fee payment window open |
| Nov 10 2016 | 6 months grace period start (w surcharge) |
| May 10 2017 | patent expiry (for year 12) |
| May 10 2019 | 2 years to revive unintentionally abandoned end. (for year 12) |